Press Releases

Press Releases

Date Title & Summary Additional Formats
12/01/20
Cidara Therapeutics to Present Preclinical Data for Influenza AVCs at the 7th ESWI Influenza Conference
SAN DIEGO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced a keynote lecture, an oral
11/30/20
Cidara Therapeutics to Present New Clinical Data for Rezafungin at ESICM LIVES 2020
SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present three posters at
11/16/20
Cidara Therapeutics Named a San Diego Metro Area Top Workplace for the Fourth Consecutive Year
Employee feedback places Cidara among top 20 small companies in the area SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal
11/11/20
Cidara Therapeutics to Participate in Two Upcoming Investor Conferences
SAN DIEGO , Nov. 11, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President
11/05/20
Cidara Provides Corporate Update and Reports Third Quarter 2020 Financial Results
SAN DIEGO , Nov. 05, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the three
10/21/20
Cidara Therapeutics Announces New Clinical and Preclinical Data for Rezafungin and Influenza AVCs at IDWeek 2020
Presentations   highlight clinical and preclinical progress of long-acting drug candidates for serious fungal and viral infections Posters presenting new a nalyses from completed Phase 2 STRIVE trial support   the efficacy and pharmacokinetics of once-weekly rezafungin in the treat ment   of
10/13/20
Cidara Therapeutics to Present at the 2020 American College of Clinical Pharmacy (ACCP) Annual Meeting
SAN DIEGO , Oct. 13, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present two posters at
09/14/20
Cidara Therapeutics to Present New Clinical and Preclinical Data for Rezafungin and Influenza AVCs at IDWeek 2020
SAN DIEGO , Sept. 14, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present two oral
09/02/20
Cidara Therapeutics to Participate in Upcoming Investor Conferences
SAN DIEGO , Sept. 02, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein , Ph.D., President and
08/13/20
Cidara Provides Corporate Update and Reports Second Quarter 2020 Financial Results
SAN DIEGO , Aug. 13, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the three months ended